Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells.
Therapeutic efficacy of a synthetic somatostatin analogue for the treatment of carcinoid tumors is still controversial. In vivo studies performed in our laboratory showed that a somatostatin analogue, SMS 201-995, significantly inhibited growth of human pancreatic carcinoid (BON) tumors xenotransplanted into athymic nude mice. In the present study, however, SMS 201-995 did not inhibit in vitro growth of BON cells, but rather SMS 201-995 stimulated growth in a dose-dependent fashion. The growth-stimulatory effect was likely mediated through the reduction of cyclic AMP production. Unsuccessful treatment of certain types of carcinoid tumor with SMS 201-995 may be partly due to the direct growth-stimulatory effect of SMS 201-995 on carcinoid cells.
Department of Surgery, University of Texas Medical Branch, Galveston 77555-0527.
J
J
Ishizuka
R D
RD
Beauchamp
B M
BM
Evers
C M
CM
Townsend
J C
JC
Thompson
D002276:Carcinoid Tumor / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects*; D000242:Cyclic AMP / Q000378:metabolism; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D015282:Octreotide / Q000494:pharmacology*; D010716:Phosphatidylinositols / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D006133:Growth Substances; D010716:Phosphatidylinositols; D013004:Somatostatin; D000242:Cyclic AMP; D015282:Octreotide